ALIM logo

Alimera Sciences, Inc.


ALIM: Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.


Show ALIM Financials

Consumer Interest
SEC Filings

Recent trades of ALIM by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quiver Logo

No Whale Activity for this ticker

Institutional Holdings Dashboard

Quarterly net insider trading by ALIM's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Methods of treating retinal diseases Aug. 02, 2022
  • Patent Title: Ocular implantation device Dec. 26, 2017
  • Patent Title: Method of reducing incidence of intraocular pressure associated with intraocular use of corticosteroids Mar. 26, 2013
Government Contracts

Federal grants, loans, and purchases


Number of mentions of ALIM in WallStreetBets Daily Discussion


Recent insights relating to ALIM

CNBC Recommendations

Recent picks made for ALIM stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ALIM

Corporate Flights

Flights by private jets registered to ALIM